Evidence map›Paper›PMID 37814796›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2023

Alpha-1 antitrypsin inhibits fractalkine-mediated monocyte-lung endothelial cell interactions.

Andrew Mikosz, Kevin Ni, Fabienne Gally, Katherine A Pratte, Seth Winfree, Qiong Lin, Isabelle Echelman, Brianna Wetmore, Danting Cao, Matthew J Justice and 6 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Alterations in CX3CL1 Levels and Its Role in Viral Pathogenesis.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Andrew MikoszDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Kevin NiDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.ORCID 0000-0002-9707-3091
Fabienne GallyDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, Colorado, United States.ORCID 0000-0003-0503-7411
Katherine A PratteDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.ORCID 0000-0003-3358-8907
Seth WinfreeDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Indiana University, Indianapolis, Indiana, United States.ORCID 0000-0002-2396-5871
Qiong LinDepartment of Medicine, Fuzhou First Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian, China.
Isabelle EchelmanDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Brianna WetmoreDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Danting CaoDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Matthew J JusticeDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Robert A SandhausDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Lisa MaierDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Charlie StrangeDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina, United States.
Russell P BowlerDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.
Irina PetracheDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.ORCID 0000-0003-1094-2600
Karina A SerbanDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.ORCID 0000-0002-9372-3034
National Jewish Health · USFujian Medical University · CNIndiana University – Purdue University Indianapolis · USMedical University of South Carolina · US

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
Sarcoidosis and A1AT Genomics & Informatics CenterU01HL112707 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECICH, MICHAEL JOHN, KAMINSKI, NAFTALI · 2012 to 2015
$8.5M
Ceramide-induced Lung Destruction in EmphysemaR01HL077328 · NHLBI · NATIONAL JEWISH HEALTH · PI PETRACHE, IRINA · 2006 to 2024
$8.0M
Role of FABP5 in COPD ExacerbationsR01HL141264 · NHLBI · NATIONAL JEWISH HEALTH · PI Fabienne Gally · 2019 to 2026
$3.7M
Mannose binding lectin-dependent complement activation in emphysemaK08HL141770 · NHLBI · NATIONAL JEWISH HEALTH · PI SERBAN, KARINA · 2019 to 2023
$793k
Immunologic and Molecular Phenotypes in AATD and SarcoidosisU01HL112695 · NHLBI · NATIONAL JEWISH HEALTH · PI MAIER, LISA A · 2012 to 2014
$465k
NHLBI NIH HHS K08 HL141770NHLBI NIH HHS R01 HL077328NHLBI NIH HHS R01 HL141264NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NHLBI NIH HHS U01 HL112695NHLBI NIH HHS U01 HL112707
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by nonresolving inflammation fueled by breach in the endothelial barrier and leukocyte recruitment into the airspaces. Among the ligand-receptor axes that control leukocyte recruitment, the full-length fractalkine ligand (CX3CL1)-receptor (CX3CR1) ensures homeostatic endothelial-leukocyte interactions. Cigarette smoke (CS) exposure and respiratory pathogens increase expression of endothelial sheddases, such as a-disintegrin-and-metalloproteinase-domain 17 (ADAM17, TACE), inhibited by the anti-protease α-1 antitrypsin (AAT). In the systemic endothelium, TACE cleaves CX3CL1 to release soluble CX3CL1 (sCX3CL1). During CS exposure, it is not known whether AAT inhibits sCX3CL1 shedding and CX3CR1

Indexed as

Chemokine CX3CL1Pulmonary Emphysemaalpha 1-AntitrypsinAnimalsCell CommunicationCX3C Chemokine Receptor 1Endothelial CellsEndotheliumHumansInflammationLigandsLipopolysaccharidesLungMiceMonocytesalpha 1-AntitrypsinChemokine CX3CL1CX3C Chemokine Receptor 1CX3CL1 protein, humanCx3cl1 protein, mouseLigandsLipopolysaccharidesSERPINA1 protein, humancell-cell interactioncigarette smokingsoluble fractalkineTACEα-1 antitrypsin

Identifiers

PMID37814796
PMCPMC11068395
OpenAlexW4387472301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.